Primary dermal melanoma: A unique subtype of melanoma to be distinguished from cutaneous metastatic melanoma : A clinical, histologic, and gene expression–profiling study - 15/11/14
Abstract |
Background |
Primary dermal melanoma (PDM) is a subtype of melanoma confined to the dermis that may be morphologically impossible to distinguish from cutaneous metastatic melanoma (CMM).
Objective |
We sought to better characterize PDM by describing the clinical, histologic, and molecular features of 49 cases of PDM and determine whether a gene expression–profiling test could help distinguish PDM from CMM.
Methods |
We describe 49 cases of PDM and determined whether any clinical or histopathologic features had a statistically significant relationship with outcome. Secondly, we performed a melanoma gene expression–profiling test on a subset of the PDM and CMM cases.
Results |
Overall recurrence was infrequent and seen in 9 of 49 cases. Six patients had locoregional recurrences and 3 patients had distant metastasis. None of the clinical or histologic parameters showed a statistically significant relationship with recurrence. There was a statistically significant association of a class I signature by DecisionDx-Melanoma assay (Castle Biosciences Inc, Friendswood, TX) for PDM whereas CMM were more frequently class II (P value = .023).
Limitations |
The mean follow-up time was 26 months.
Conclusions |
Most conventional staging parameters used for prognosis in cutaneous melanoma have limited applicability to PDM. The melanoma prognostic assay may be a useful tool for distinguishing PDM from CMM.
Le texte complet de cet article est disponible en PDF.Key words : American Joint Committee on Cancer, cutaneous metastatic melanoma, fluorescence in situ hybridization, gene expression profile, melanoma, primary dermal melanoma
Abbreviations used : CGH, CMM, FISH, GEP, IDN, IHC, NOS, PDM, SLNB
Plan
Supported by the Irene D. Pritzker Foundation and partially supported by Castle Biosciences Inc. |
|
Disclosure: Dr Gerami has served as a consultant to Castle Biosciences Inc, Myriad Genetics, and DermTech Inc, receiving honoraria. Dr Guitart has served as a consultant to Castle Biosciences Inc, receiving honoraria. The other authors declared no conflicts of interest. |
|
Dr Sidiropoulos and Ms Obregon contributed equally to this article. |
Vol 71 - N° 6
P. 1083-1092 - décembre 2014 Retour au numéroBienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.
Déjà abonné à cette revue ?